Abstract
Diabetes mellitus in rats is characterized by excessive activity of several matrix metalloproteinases (MMPs), notably collagenase(s) and gelatinase(s), in skin, gingiva, and other tissues. A number of tetracyclines (TCs), both antimicrobial compounds as well as chemically modified non-antimicrobial TC analogues (CMTs) are known to possess potent inhibitory activity against these enzymes. Three conventional antimicrobial TCs and six CMTs were used in this study. In vitro, doxycycline was shown to possess higher inhibitory capacity (i.e. lower IC 50 ) against diabetic rat skin collagenase than either minocycline or tetracycline HCl. Addition of excess zinc partially reversed the proteinase inhibition by TCs. In vivo, using rats made diabetic with streptozotocin (STZ), oral administration of various TCs led to decreased weight loss and substantial reductions in the activity of both skin collagenase and skin gelatinase (primarily MMP-9, 92 kDa) without affecting blood glucose. Using an in vitro spectrophotometric technique, the Zn positive2 reactivity of several CMTs was assessed and found to be positively related to the potency of these compounds as MMP inhibitors. One particular CMT (CMT-5, pyrazole analogue), which is neither antimicrobial nor capable of binding metal cations, did not inhibit the MMPs. TCs have potential utility in management of diabetic complications mediated by excessive activity of MMPs.
Keywords: matrix metalloprotienase activity, tetracycline analogues, streptozotocin STZ, matrix metalloproteinase, chemotheraputics, non antimicrobial CMTs, organomercurial agent, aminophenylmercuric acetate, zinc binding studies, pyrazole analogue, collagenase and gelatinase activity
Current Medicinal Chemistry
Title: Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity
Volume: 8 Issue: 3
Author(s): Maria E. Ryan, Adil Usman, N. S. Ramamurthy, Lorne M. Golub and Robert A. Greenwald
Affiliation:
Keywords: matrix metalloprotienase activity, tetracycline analogues, streptozotocin STZ, matrix metalloproteinase, chemotheraputics, non antimicrobial CMTs, organomercurial agent, aminophenylmercuric acetate, zinc binding studies, pyrazole analogue, collagenase and gelatinase activity
Abstract: Diabetes mellitus in rats is characterized by excessive activity of several matrix metalloproteinases (MMPs), notably collagenase(s) and gelatinase(s), in skin, gingiva, and other tissues. A number of tetracyclines (TCs), both antimicrobial compounds as well as chemically modified non-antimicrobial TC analogues (CMTs) are known to possess potent inhibitory activity against these enzymes. Three conventional antimicrobial TCs and six CMTs were used in this study. In vitro, doxycycline was shown to possess higher inhibitory capacity (i.e. lower IC 50 ) against diabetic rat skin collagenase than either minocycline or tetracycline HCl. Addition of excess zinc partially reversed the proteinase inhibition by TCs. In vivo, using rats made diabetic with streptozotocin (STZ), oral administration of various TCs led to decreased weight loss and substantial reductions in the activity of both skin collagenase and skin gelatinase (primarily MMP-9, 92 kDa) without affecting blood glucose. Using an in vitro spectrophotometric technique, the Zn positive2 reactivity of several CMTs was assessed and found to be positively related to the potency of these compounds as MMP inhibitors. One particular CMT (CMT-5, pyrazole analogue), which is neither antimicrobial nor capable of binding metal cations, did not inhibit the MMPs. TCs have potential utility in management of diabetic complications mediated by excessive activity of MMPs.
Export Options
About this article
Cite this article as:
Ryan E. Maria, Usman Adil, Ramamurthy S. N., Golub M. Lorne and Greenwald A. Robert, Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity, Current Medicinal Chemistry 2001; 8 (3) . https://dx.doi.org/10.2174/0929867013373598
DOI https://dx.doi.org/10.2174/0929867013373598 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry High Prevalence of Vitamin D Deficiency and Correlation with Cystatin-C and Other Cardiovascular and Renal Risk Biomarkers in Patients with Type 2 Diabetes Mellitus Complicated with Hypertension
Current Diabetes Reviews Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets The Impact of Pregnancy and Parity on Type 1 Diabetes Complications
Current Diabetes Reviews TrkB Receptor Agonist 7, 8 Dihydroxyflavone Triggers Profound Gender- Dependent Neuroprotection in Mice After Perinatal Hypoxia and Ischemia
CNS & Neurological Disorders - Drug Targets Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Sirtuin3 in Neurological Disorders
Current Drug Research Reviews Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis
Drug Metabolism Letters Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Editorial (Thematic Issue: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications)
CNS & Neurological Disorders - Drug Targets Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research The Role of Calcium Stores in Apoptosis and Autophagy
Current Molecular Medicine Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials